title: Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP.
authors.affiliation: Department of Hematology.
authors.forename: K
authors.initials: K
authors.lastname: Maie
authors.forename: Y
authors.initials: Y
authors.lastname: Okoshi
authors.forename: N
authors.initials: N
authors.lastname: Takaiwa
authors.forename: N
authors.initials: N
authors.lastname: Kurita
authors.forename: Y
authors.initials: Y
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Homma
authors.forename: K
authors.initials: K
authors.lastname: Ishii
authors.forename: Y
authors.initials: Y
authors.lastname: Kohda
authors.forename: S
authors.initials: S
authors.lastname: Chiba
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000077608:Aprepitant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004347:Drug Interactions; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000932:Antiemetics; D009025:Morpholines; D000077608:Aprepitant; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone